REG +7.6%: A strong first-half result drove solid gains despite acquisition costs weighing on statutory profit.
- Revenue $745m, +20% YoY, ahead of consensus
- EBITDA $125m, +8% YoY; underlying NPAT $29.7m, comfortably above expectations
- FY26 EBITDA guidance $130–135m reaffirmed
- FY28 target of 10,000 beds maintained, with growth via greenfields and acquisitions
A nice, solid update from the aged care provider today following a very choppy last 12 months where earnings have disappointed.
MM is cautiously bullish REG under $7.00
Add To Hit List
